KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Equity Average: 2010-2025

Historic Equity Average for Emergent BioSolutions (EBS) over the last 15 years, with Sep 2025 value amounting to $559.4 million.

  • Emergent BioSolutions' Equity Average rose 25.04% to $559.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.4 million, marking a year-over-year increase of 25.04%. This contributed to the annual value of $566.0 million for FY2024, which is 44.42% down from last year.
  • Emergent BioSolutions' Equity Average amounted to $559.4 million in Q3 2025, which was up 2.74% from $544.5 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Equity Average high stood at $1.6 billion for Q1 2022, and its period low was $447.4 million during Q3 2024.
  • Moreover, its 3-year median value for Equity Average was $559.4 million (2025), whereas its average is $693.1 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Equity Average soared by 37.46% in 2021, and later crashed by 52.26% in 2023.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Equity Average stood at $1.6 billion in 2021, then fell by 10.00% to $1.4 billion in 2022, then plummeted by 52.26% to $673.2 million in 2023, then fell by 26.39% to $495.6 million in 2024, then grew by 25.04% to $559.4 million in 2025.
  • Its last three reported values are $559.4 million in Q3 2025, $544.5 million for Q2 2025, and $517.8 million during Q1 2025.